December 20, 2017 / 8:40 PM / 9 months ago

BRIEF-Bristol-Myers Squibb Receives FDA Approval For Opdivo As Treatment For Patients With A Type Of Skin Cancer

Dec 20 (Reuters) - Bristol-Myers Squibb Co:

* BRISTOL-MYERS SQUIBB RECEIVES FDA APPROVAL FOR OPDIVO (NIVOLUMAB) AS ADJUVANT THERAPY IN PATIENTS WITH COMPLETELY RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below